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Metabolic syndrome (MS) refers to clustering of features related to increased risk of
cardiovascular disease, which include obesity or central obesity, dyslipidemia, dia-
betes mellitus or insulin resistance, together with hypertension. The prevalence of
MS in end-stage renal failure patients on peritoneal dialysis is quite common,
ranging from 40% to 60%, depending on the population studied and the deﬁnition
used. However, there are controversies about the clinical outcome of patients with
MS, particularly in the area of obesity. Whether peritoneal dialysis predisposes
patients to MS is another unsolved issue. Despite these controversies, preventing
patients from developing MS is important, at least from a theoretical point of view.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The concept of metabolic syndrome
The concept of metabolic syndrome (MS) arose as early as in
1950s when the association of upper body obesity with car-
diovascular disease and diabetes mellitus was observed [1]. In
1988, Reaven [2] used the term “syndrome X” to describe the
clustering association between insulin resistance, hyperglyce-
mia, hypertension, low high-density lipoprotein (HDL) choles-
terol, and raised very low-density lipoprotein triglycerides
(TGs), but obesity was not included as part of this syndrome.
The association of obesity and features of syndrome X caught
much attention thereafter andwas loosely described asMS. The
World Health Organization (WHO) ﬁrst attempted to deﬁne MS
in 1998 [3]. It included diabetes mellitus, fasting hyperglyce-
mia, impaired glucose tolerance, or insulin resistance as one of
the mandatory criteria, together with 2 or more of the
following 4 criteria: obesity or increased waist-to-hip ratio
(WHR), dyslipidemia (raised TGs or reduced HDL cholesterol),
hypertension, and microalbuminuria. In 1999, the European
Group for the Study of Insulin Resistance deﬁned MS in acine, Tung Wah Hospital,
ty of Nephrology. Published b
/4.0/).slightly different way. It also used insulin resistance or fasting
hyperinsulinemia as a mandatory criterion. Fasting hypergly-
cemia was regarded as an optional criterion [4]. Similar to the
WHO deﬁnition, apart from the mandatory criterion, the Eu-
ropean Group for the Study of Insulin Resistance also required 2
or more of 4 optional criteria, including fasting hyperglycemia,
central obesity (deﬁned by WHR), dyslipidemia (raised TGs or
reduced HDL cholesterol), and hypertension. However, the
deﬁnition of the different criteria slightly varies. In 2001, Na-
tional Cholesterol Education Program's Adult Treatment Panel
III (NCEP-ATPIII) of the United States deﬁned MS in a different
way [5]. There was no mandatory criterion. It requires 3 or
more of 5 optional criteria, namely central obesity, hyper-
triglyceridemia, reduced HDL cholesterol, high blood pressure,
and fasting hyperglycemia. It separated hyperglyceridemia and
reduced HDL cholesterol into 2 different criteria and did not
need the deﬁnition based on insulin resistance. In 2004, the
International Diabetes Federation stressed the importance of
central obesity by putting raisedWHR as amandatory criterion,
together with any 2 of the other 4 optional criteria including
hypertriglyceridemia, reduced HDL cholesterol, high blood
pressure, and fasting hyperglycemia, impaired glucose toler-
ance, or insulin resistance [6]. Because of some obvious limi-
tation in using waist circumference to reﬂect central obesity in
peritoneal dialysis (PD) patients, Li et al [7] suggested tomodifyy Elsevier. This is an open access article under the CC BY-NC-ND license
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tients by replacing central obesity according to body mass in-
dex (BMI) for Caucasians and Asians. The details of different
deﬁnitions are summarized in Table 1.
Pathophysiology of MS
Despite the variation in the ﬁne details of the deﬁnitions, the
MS basically clusters around central obesity. Central obesity is
reﬂective of increased visceral fat, which is expected to have a
higher rate of ﬂux of adipose tissueederived free fatty acid into
the liver through the splanchnic circulation leading to
increased very low-density lipoprotein production, hyper-
triglyceridemia, increased glucose release from the liver into
systemic circulation and subsequent hyperinsulinemia, and
insulin resistance [8]. In addition, visceral fat has been docu-
mented to have higher capacity to release proinﬂammatory
cytokines such as tumor necrosis factor-a, interleukin-6, and C-
reactive protein. A higher level of these cytokines is identiﬁed
in MS [9] and in PD patients with obesity [10] and increased
visceral fat [11]. Visceral fat, instead of subcutaneous fat, and
waist circumference have also been demonstrated to be asso-
ciated with atherosclerosis and cardiovascular disease in PD
patients [12e14].
Prevalence of MS in PD patients
In the last few decades, obesity and diabetes mellitus have
become an epidemic in many countries. It is expected that the
incidence of MS is on the rise too. In general, the prevalence
ranges from 20% to 40%, and a higher prevalence was found in
more afﬂuent countries and in the older population [8].
As expected, the prevalence of MS in PD patients also varies
between countries and according to different deﬁnitions used.Table 1. Summary of different deﬁnitions of metabolic syndrome
Organization WHO EGIR NC
Reference [3] [4] [5]
Year 1998 1999 200
Criteria required 1 mandatory þ 2 others
or more
1 mandatory þ 2 others
or more
An
Obesity BMI >30 or W/H
ratio >0.9 (M),
>0.85 (F)
Central obesity: waist
circumference
>94 cm (M),
>80 cm (F)
Cen
w
>
>
TG TG 1.7 or HDL-chol
<0.9 (M),
<1.0 (F)
TG >2.0 or HDL-chol
<1.0
TG
HDL chol HD
<
Insulin
resistance or
hyperglycemia
DM, impaired fasting
glucose, IGT,
insulin resistance
(mandatory)
Insulin resistance,
fasting
hyperinsulinemia
(> 75 percentile of
non-DM)
(mandatory)
FBS
FBS 6.1
Hypertension >140/90 140/90 or on
medication
1
m
Others Microalbuminuria >20
mg/min
All biochemistry units are in mmol/L unless speciﬁed, BMI unit is in kg/m2.
Unit conversion: TG 1 mmol/L¼ 88.5 mg/dL, HDL chol 1 mmol/L¼ 38.6 mg/
BMI, body mass index; DM, diabetes mellitus; EGIR, European Group for th
density lipoprotein cholesterol; IDF, International Diabetes Federation; IGT, i
Program's Adult Treatment Panel III; TG, triglyceride; WHO, World Health OSzeto et al [15] compared the prevalence of MS in a single
center in Hong Kongwith 329 prevalent patients, including 31%
of diabetics, and noted that the prevalence rates ranged from
53% to 66%, with higher prevalence according to the modiﬁed
NCEP-ATPIII and then followed by the NCEP-ATPIII. Dong et al
[16] found that the prevalence of MS in China from a multi-
center study involving 4 different regions of China including
40% of diabetics was 55.4% according to NCEP-ATPIII. If di-
abetics are excluded, it is expected that the prevalence should
be lower. In Taiwan, Liao et al [17] found that the prevalence
was 52.9% among all PD patients, and it was 39.4% when di-
abetics were excluded. However, Prasad et al [18] reported
51.3% among nondiabetic PD patients. Therefore, there is sub-
stantial variation between countries and ethnicity, but the
overall impression is that the prevalence is substantially higher
than that in the general population even when diabetics are
excluded.Controversies about MS in PD patients
Clinical outcome of PD patients with MS
There is little argument against the detrimental effect of
diabetes on patient survival among PD patients, yet it was
arguable whether MS or its individual elements such as obesity,
new-onset hyperglycemia, or dyslipidemia have effect on pa-
tient survival in PD patients. This is largely affected by the well-
known reverse epidemiology in many different risk factors
observed in dialysis patients.
There were both reports on the presence and absence of
negative impact of MS on patient survival. Szeto et al [15]
found that, among the 4 different deﬁnitions, only MS ac-
cording to WHO carried an increased risk of mortality. But
among the nondiabetics (n ¼ 196), there was no signiﬁcantEP-ATPIII Modiﬁed NCEP-ATPIII IDF
[7] [6]
1 2008 2005
y 3 or more Any 3 or more 1 mandatory þ
2 others
tral obesity:
aist circumference
102 cm (M),
88 cm (F)
BMI >30 for Caucasians
or >25 for Asians
Waist circumference
(ethnic speciﬁc)
(mandatory)
1.7 TG 1.7 TG >1.7
L-chol <1.0 (M),
1.3 (F)
HDL-chol <1.0 (M),
<1.3 (F)
HDL-chol <1.03 (M),
<1.29 (F), or on
treatment
6.1 FBS 6.1 FBS > 5.6, or DM,
or IGT
35/85 or on
edication
135/85 135/85 or on
medication
dL.
e Study of Insulin Resistance; FBS, fasting blood sugar; HDL chol, high-
mpaired glucose tolerance; NCEP-ATPIII, National Cholesterol Education
rganization; W/H ratio, waist-to-hip ratio.
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which deﬁnition was used. In a smaller study from Taiwan on
139 nondiabetic PD patients, MS, as deﬁned according to
NCEP-ATPIII, was found to be only associated with inﬂamma-
tory markers but not patient survival [19]. However, although
also from Taiwan and using the same NCEP-ATPIII deﬁnition,
Liao et al [17] found that incident nondiabetic PD patients
(n ¼ 280) with MS had poorer patient survival compared to
those without MS for both total and cardiovascular eventefree
patient survival. Similarly, higher patient mortality was found
in the nondiabetic Indian PD patients with MS compared to
those without (n ¼ 163) [18]. Sample size variation may be an
explanation for the different conclusions. A large-scale study is
needed to address this issue.
Impact of obesity on patient survival
The most popular parameter to represent obesity is BMI for
its simplicity and general correlation with fat mass. However,
the amount of fat tissue for the same BMI varies between
ethnicity; thus, the WHO has different criteria of BMI to reﬂect
obesity for the Caucasians and Asians [20]. In patients on he-
modialysis (HD), it is well recognized that the reverse epide-
miology phenomenon exists with protective effect onmortality
with high BMI [21]. However, this is controversial in PD pa-
tients. There have been reports on reduced, similar, and
increased mortality risk with obesity. It is plausible that
ethnicity may have interfered the effect of obesity on mortality.
For example, there was difference in effect in the Caucasians
and aboriginals according to the Australia New Zealand Dialysis
and Transplant Registry [22]. The recent reports from several
Asian countries added into this controversy. Zhou et al [23]
found an increased mortality risk in PD patients in China with
BMI over 25 kg/m2. In Hong Kong, we have analyzed the rela-
tionship between BMI and mortality among incident PD pa-
tients in Hong Kong, excluding those with Kt/V failed to be
adjusted to above 1.7/wk, and found that the increased risk
with obesity mainly existed in diabetic patients and patients
with pre-existing cardiovascular diseases [24]. The increased
risk was minimal among nondiabetic patients. Kim et al [25]
from Korea and Prasad et al [26] from India found similar risk
of mortality between their obese and normal BMI patients. The
reasons for the different observations still need to be identiﬁed,
but it may be related to the duration of study (longest in our
study in Hong Kong), prevalence of diabetes mellitus and car-
diovascular disease, and the level of solute clearance indices
achieved. When using BMI to reﬂect obesity, we have to bear in
mind that it also reﬂects the hydration status and it cannot
differentiate the body weight from muscle mass or fatty tissue.
Using creatinine excretion as a reﬂection of muscle mass,
Ramkumar et al [27] found that the amount of creatinine
excretion was predictive of survival rather than the BMI, sug-
gesting that muscle mass is protective against mortality in PD
patients. BMI also does not differentiate central obesity from
generalized obesity. Future studies should also focus on the
effect of central obesity on patient survival.
Weight changes after PD and its impact on survival
Increasing weight and obesity is commonly found in pa-
tients started on PD. In a large-scale cohort from Brazil, 60% of
PD patients were noted to have increase in body weight morethan 3% in the ﬁrst year and 20% had gained more than 7% of
weight [28]. However, patients who gained weight did not have
an increased risk of mortality compared to those with stable
weight. In contrast, those who lost weight more than 3% had
increased mortality risk. In a small-scale study using the
computed tomography scan to assess the amount of fat gained
over the ﬁrst year of PD, Choi et al [29] found that there was
substantial increase in both subcutaneous and visceral fat in the
ﬁrst 6 months, but there was no further increase in the next 6
months, suggesting that fat tissue gain mainly occurs in the
initial phase of PD. In our own series, 58% of patients gained
more than 5% body weight in the ﬁrst year, and this occurred
more in patients with low and normal BMI. There was no
increased mortality risk observed in this group of patients.
Instead, a slightly reduced mortality risk, though statistically
insigniﬁcant, was observed in the overweight and obese pa-
tients who had weight loss over 5% in the ﬁrst year (unpub-
lished data) suggesting that weight reduction in the overweight
PD patients may be beneﬁcial to their survival. It is highly
plausible that the effect of weight gain or loss differs among
patients with different baseline BMI. This needs further inves-
tigation. When addressing the issue of weight gain or reduc-
tion, we also need to ask whether this is a healthy gain or loss.
Is it true that weight gain is more common in PD than in HD
patients? Therewas a report comparing the weight gain among
propensity scoreematched PD and HD patient cohort. In
contrast to the common impression, it is found that PD patients
actually had less weight gain compared to HD patients [30].
Pellicano et al [31] did a small-scale comparative study inves-
tigating the body composition change between different dial-
ysis modalities. They found that both PD and HD patients
gained weight similarly, but PD patients tend to gain more
visceral fat. It is desirable to have a prospective study on the
patterns of weight changes among different dialysis modalities
and their impact on patient survival, respectively. If we believe
that gaining visceral fat is proinﬂammatory, we should develop
measures to prevent the increase in visceral fat.
New-onset hyperglycemia
Szeto et al [32] looked at nondiabetic patients started on
continuous ambulatory peritoneal dialysis (CAPD), and fasting
blood sugar was taken 4 weeks after CAPD commenced. He
found that 23.4% of patients had increased fasting blood sugar
including 4.4% with fasting blood sugar over 200 mg/dL
(11.1 mmol/L). Age and comorbidity but not obesity and glucose
load were associated with new-onset hyperglycemia.
Compared to patients with fasting blood sugar below 100 mg/
dL, those above 100mg/dL had poorer survival after 12 months.
However, these patients had 1.5% dextrose dialysate overnight
dwell. In our own experience, fasting blood sugar often returns
to normal if they had empty peritoneal cavity overnight. In
addition, owing to its association with older age and comor-
bidity, the association with poorer survival had to be inter-
pretedwith care. Liao et al [17] reported that only 5% of patients
developed de novo diabetes after a mean follow-up of 49
months.
Is glucose load from PD predisposed patients to new-onset
hyperglycemia? Szeto et al [32] did not ﬁnd the association.
Woodward et al [33] analyzed the new-onset diabetes mellitus
before and after renal transplantation in PD and HD patients;
they found that in 2 years before transplantation, 12.7% of HD
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10.7% in PD patients. Similarly, more HD patients developed
new-onset diabetes than PD patients after transplantation. In a
prospective randomized control trial on using low glucose load
biocompatible dialysate (the Hong Kong PEN study-one to two
bags of 1.5% Physioneal, one bag of Extraneal and one bag of
Nutrineal vs. conventional Dianeal, peritoneal dialysate ﬂuid
products from Baxter Healthcare) versus conventional Dianeal,
there was no difference in fasting blood sugar, TG, low-density
lipoprotein, and HDL cholesterol after 1 year [34]. Thus, there
was no strong evidence that glucose load or PD per se increased
risk of new-onset diabetes or hyperglycemia in PD patients. A
recent publication on insulin resistance in nondiabetic PD pa-
tients showed that it was related to obesity rather than glucose
load or peritoneal transport [35].
Prevention of MS in PD patients
Liao et al [17] reported that the proportion of patients with
MS had increased from 41% to 65% over a mean follow-up of 49
months. Although the signiﬁcance of MS on survival is still
controversial, prevention of MS development should be our
target until proven otherwise. There was no randomized
control trial on the efﬁcacy of different means to prevent MS in
PD patients. We should minimize the glucose load as much as
possible as this carries the potential advantage of gaining less
visceral fat and less dyslipidemia, although its effect on
reducing new-onset diabetes still waits to be proved. Exercise
and diet control is another area that should be explored. We
had shown that fasting blood sugar can be reduced after a 3-
month exercise program for PD patients compared to non-
randomized controls, with a marginal increase of HDL choles-
terol [36]. Pennell et al [37] developed a weight management
program involving dietary and exercise advice and monitoring,
using which body weight could be reduced signiﬁcantly in 16%
of obese patients. Research into this area is needed.
Conclusion
Both preexisting and new-onset MS and its components are
very common among end-stage renal failure patients on PD.
Although the signiﬁcance of it is still controversial, given the
current understanding of its pathophysiology, we should pre-
vent the development of MS in our PD patients. This may
involve minimization of glucose load, dietary modiﬁcation, and
exercise.
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